166 related articles for article (PubMed ID: 38748286)
61. Improving the Classification of PCNSL and Brain Metastases by Developing a Machine Learning Model Based on
Cui C; Yao X; Xu L; Chao Y; Hu Y; Zhao S; Hu Y; Zhang J
J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983721
[No Abstract] [Full Text] [Related]
62. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.
Kawai N; Zhen HN; Miyake K; Yamamaoto Y; Nishiyama Y; Tamiya T
J Neurooncol; 2010 Nov; 100(2):225-32. PubMed ID: 20390437
[TBL] [Abstract][Full Text] [Related]
63. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
64. Geometrical Comparison and Quantitative Evaluation of
Li H; Li J; Li F; Zhang Y; Li Y; Guo Y; Xu L
Front Oncol; 2021; 11():772428. PubMed ID: 35004291
[TBL] [Abstract][Full Text] [Related]
65. Clinicopathological and molecular predictors of [
Llombart-Cussac A; Prat A; Pérez-García JM; Mateos J; Pascual T; Escrivà-de-Romani S; Stradella A; Ruiz-Borrego M; de Las Heras BB; Keyaerts M; Galvan P; Brasó-Maristany F; García-Mosquera JJ; Guiot T; Gion M; Sampayo-Cordero M; Di Cosimo S; Pérez-Escuredo J; de Frutos MA; Cortés J; Gebhart G
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38587643
[TBL] [Abstract][Full Text] [Related]
66. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
67. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
[TBL] [Abstract][Full Text] [Related]
68. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
Kosmala A; Duell J; Schneid S; Serfling SE; Higuchi T; Weich A; Lapa C; Hartrampf PE; Raderer M; Einsele H; Buck AK; Topp MS; Schlötelburg W; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):749-755. PubMed ID: 37943339
[TBL] [Abstract][Full Text] [Related]
69. Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.
Inoue Y; Asano Y; Satoh T; Tabata K; Kikuchi K; Woodhams R; Baba S; Hayakawa K
Asia Ocean J Nucl Med Biol; 2014; 2(2):87-94. PubMed ID: 27408864
[TBL] [Abstract][Full Text] [Related]
70. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
71. A head-to-head comparison of
Qin C; Liu F; Huang J; Ruan W; Liu Q; Gai Y; Hu F; Jiang D; Hu Y; Yang K; Lan X
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3228-3237. PubMed ID: 33609152
[TBL] [Abstract][Full Text] [Related]
72. Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A
Neuro Oncol; 2024 Feb; ():. PubMed ID: 38366824
[TBL] [Abstract][Full Text] [Related]
73. Semi-quantitative analysis of
Ravikanth R; Singh JK
World J Nucl Med; 2020; 19(4):347-352. PubMed ID: 33623503
[No Abstract] [Full Text] [Related]
74. Report of Eleven Patients of Subcutaneous Panniculitis-Like T-Cell Lymphoma: Clinicopathologic Features,
Jiang M; Zhao L; Zheng J; Zhang J; Chen P; Zhou W
Front Oncol; 2021; 11():650822. PubMed ID: 34277404
[TBL] [Abstract][Full Text] [Related]
75. Comparison of diffusion-weighted MRI and [
Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
[TBL] [Abstract][Full Text] [Related]
76. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [
Guo W; Pang Y; Yao L; Zhao L; Fan C; Ke J; Guo P; Hao B; Fu H; Xie C; Lin Q; Wu H; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1604-1617. PubMed ID: 33179149
[TBL] [Abstract][Full Text] [Related]
77. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.
Sachpekidis C; Hillengass J; Goldschmidt H; Mosebach J; Pan L; Schlemmer HP; Haberkorn U; Dimitrakopoulou-Strauss A
Am J Nucl Med Mol Imaging; 2015; 5(5):469-78. PubMed ID: 26550538
[TBL] [Abstract][Full Text] [Related]
78. Prognostic value of [
Krebs S; Mauguen A; Yildirim O; Hatzoglou V; Francis JH; Schaff LR; Mellinghoff IK; Schöder H; Grommes C
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):3940-3950. PubMed ID: 33966087
[TBL] [Abstract][Full Text] [Related]
79. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
80. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
